Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP3-saRNA (YMN-136) Vaccine in Advanced Non-Small Cell Lung Cancer
NCT07561723Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective Response Rate at 1 year and Dose-Limiting Toxicity at 8 weeks. Started Apr 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07561723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07561723.